493.8K
Downloads
199
Episodes
Dementia Matters is a podcast about Alzheimer‘s disease and other causes of dementia. Creator and host Dr. Nathaniel Chin interviews leading scientists and caregiving experts to bring listeners the latest in Alzheimer’s disease news, research and caregiver resources. Brought to you by the Wisconsin Alzheimer’s Disease Research Center, find show notes and more resources at adrc.wisc.edu/dementia-matters.
Episodes
Tuesday Jan 24, 2023
Tuesday Jan 24, 2023
In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives.
Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council
Show Notes
Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website.
Learn more about Part the Cloud at their website.
Learn more about the Alzheimer's Association at their website.
Learn more about Dr. Pike in her bio on her website.
Learn more about Mr. Johns in his bio on his website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Jan 17, 2023
Tuesday Jan 17, 2023
Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Show Notes
In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release.
Read the FDA’s news release regarding lecanemab’s accelerated approval on their website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Jan 10, 2023
Tuesday Jan 10, 2023
Host Nathaniel Chin, MD, starts the new year by discussing modifiable risk factors for Alzheimer’s disease, commenting on building healthy lifestyle habits for the new year, and reflecting as Dementia Matters celebrates five years of production.
Show Notes
“Dementia prevention, intervention, and care: 2020 report of the Lancet Commission” is mentioned at the 4:16 mark. Read the full report on The Lancet’s website.
Our past episode, “Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage,” is mentioned at the 5:05 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.
Our past episode, “Study Finds Air Pollution a Risk Factor For Alzheimer’s Disease,” is mentioned at the 5:07 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.
Our past episode, “AARP Study Show Stigma Surrounding Dementia Among Healthcare Professionals And General Public,” is mentioned at the 5:28 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.
As mentioned at the 7:40 mark, learn more about the books The Power of Habit by Charles Duhigg and Atomic Habits by James Clear, on the authors’ respective websites.
Listen to our past episode, “Impacts of Exercise on Brain Health,” mentioned at the 9:37 mark.
Learn about the book, Why Sleep Matters by Matthew Walker, mentioned at the 11:14 mark.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Thursday Dec 29, 2022
Thursday Dec 29, 2022
It’s generally known that mitochondria are the powerhouse of cells, but did you know they can play a significant role in aging processes? Through the field of bioenergetics, scientists are looking to study how changes in mitochondria affect us as we age and their connection to Alzheimer’s disease. Dr. Russell Swerdlow joins the podcast to discuss the field of bioenergetics and how mitochondria can impact Alzheimer’s disease and other aspects of aging.
Guest: Russell Swerdlow, MD, director, Kansas Alzheimer’s Disease Research Center, director, Heartland Center for Mitochondrial Medicine, professor of neurology, University of Kansas
Show Notes
Learn more about Dr. Russell Swerdlow at his bio on the University of Kansas Medical Center’s website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Dec 13, 2022
Tuesday Dec 13, 2022
The field of biomarkers is advancing quickly, allowing preclinical Alzheimer’s disease to be identified earlier and earlier in a person’s life. As individuals learn they are at risk for Alzheimer’s years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent.
Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine
Show Notes
Read Drs. Emily Largent and Claire Erickson’s paper, “Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society,” on PubMed Central.
Learn more about Dr. Largent at her bio on the Penn Leonard Davis Institute of Health Economics website.
Learn more about Dr. Erickson at her bio on the Penn Leonard Davis Institute of Health Economics website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Nov 29, 2022
Tuesday Nov 29, 2022
Though brain and cognitive changes are typically diagnosed as one form of dementia, recent studies have shown that mixed dementia is more common than previously thought. Mixed dementia, also known as Multiple-etiology dementia, is a condition where brain changes are caused by more than one neurological disease, such as Alzheimer’s disease, Lewy body dementia (LBD), or frontotemporal dementia. Dr. Roderick Corriveau joins the podcast to discuss what is known about mixed dementia and how the field of studying neurological diseases is advancing to diagnose and treat this condition.
Guest: Roderick Corriveau, PhD, program director, National Institute of Neurological Disorders and Stroke (NINDS), NIH Lead, Alzheimer’s Disease-Related Dementias (ADRD) Summits
Show Notes
Read more about the National Institutes of Neurological Disorders and Stroke (NINDS) campaign, “Mind Your Risks,” at the Mind Your Risks website.
Learn more about mixed dementia on the Alzheimer’s Association website.
Learn more about Dr. Corriveau at his bio on the National Institutes of Neurological Disorders and Stroke website.
Learn more about NINDS on their website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Nov 15, 2022
Tuesday Nov 15, 2022
Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves.
Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania
Show Notes
Read Dr. Jason Karlawish and Dr. Josh Grill’s viewpoint piece, “Disclosing Alzheimer Disease Biomarker Results to Research Participants,” from JAMA Neurology’s June 2022 issue.
Listen to our episode with Dr. Daniel Gibbs about his book (mentioned by Dr. Karlawish at 34:21) on our website, Spotify, Apple Podcasts, or wherever you listen.
Listen to our past episode on amyloid disclosures with research participants on our website, Spotify, Apple Podcasts, or wherever you listen.
Learn more about Dr. Josh Grill at his bio on the University of California - Irvine website.
Learn more about Dr. Jason Karlawish’s work at his website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Nov 01, 2022
Tuesday Nov 01, 2022
Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 6
Concluding our special series on the 2022 Spring ADRC Meeting, Dr. Cerise Elliott joins the podcast to discuss the NIA’s work within the field of Alzheimer’s disease research, how the NIA promotes open science to advance research across the ADRC program, and other key takeaways from the spring meeting.
Guest: Cerise Elliott, PhD, program director for clinical interventions and diagnostics, division of neuroscience, National Institute on Aging
Show Notes
Watch Dr. Cerise Elliott’s session from the Spring ADRC Meeting, “Q&A with Program,” on NACC’s YouTube channel.
Listen to our previous episode with Dr. Elliott, "National Priorities for Dementia and Health Disparities Research," on our website.
Learn more about Dr. Elliott at her bio on the National Institute on Aging website.
Learn more about the National Alzheimer’s Coordinating Center at their website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Oct 25, 2022
Tuesday Oct 25, 2022
Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 5
Whether it be due to new research findings, innovative approaches and ideas, or technological advancements, Alzheimer’s disease research is constantly evolving. Now, dementia research is headed into the digital frontier. Dr. Rhoda Au joins the podcast to discuss digital biomarkers, gamifying cognitive testing, and how the field of Alzheimer’s disease research is entering its digital age.
Guest: Rhoda Au, PhD, digital technology leader, Boston University Alzheimer’s Disease Research Center, co-principal investigator, director of neuropsychology, Framingham Heart Study, professor, Boston University School of Medicine
Show Notes
Watch Dr. Rhoda Au’s presentation from NACC’s Spring ADRC Meeting on NACC’s YouTube channel.
Learn more about Dr. Au at her bio on the Boston University Chobanian & Avedisian School of Medicine website.
Learn more about the National Alzheimer’s Coordinating Center at their website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Tuesday Oct 18, 2022
Tuesday Oct 18, 2022
Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 4
Brain imaging is a key tool in Alzheimer’s disease research and diagnoses, allowing scientists to see changes in the brain years, even decades, before an individual experiences symptoms of dementia. The data these images provide researchers with is incredibly useful, leading the National Alzheimer’s Coordinating Center to take up numerous efforts to standardize, unify and share this type of data across the Alzheimer’s Disease Research Centers. Dr. Beth Mormino joins the podcast to discuss the NIA’s SCAN initiative, the new “legacy” data set, and the importance of standardizing MRI and PET scan procedures to predict brain trajectories better.
Guest: Beth Mormino, PhD, assistant professor, Stanford University
Show Notes
Learn more about Dr. Mormino’s presentation on the SCAN Legacy project by reading her presentation slides on NACC’s website.
Listen to Dr. Mormino’s last episode on Dementia Matters, “The Science of Alzheimer’s Disease Risk,” on our website.
Learn more about the National Alzheimer’s Coordinating Center at their website.
Register for NACC’s Fall 2022 ADRC Meeting on their website. Registration is free and open to the public. The fall meeting, which will focus on diversity, equity, and inclusion in Alzheimer’s research, will take place on Thursday, October 20, and Friday, October 21, virtually and in person in Chicago, IL.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.